In clinical trials, MTD plays a pivotal role in determining the starting dose for human studies. It helps establish a dosage range that is likely to be safe and effective. MTD findings from preclinical studies guide the design of Phase I trials, which focus on assessing the safety, tolerability, and pharmacokinetics of new drugs.
